Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 25/100

Failure Rate

0.0%

0 terminated/withdrawn out of 3 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2
2(66.7%)
N/A
1(33.3%)
3Total
Phase 2(2)
N/A(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (3)

Showing 3 of 3 trials
NCT07393334Phase 2Recruiting

Effects of NLS-133, a Potential Non-Hormonal "On-Demand" Male Contraceptive

Role: lead

NCT07361120Phase 2Recruiting

Plan A Occlusion and Reversal System Feasibility Study

Role: lead

NCT06891729Not ApplicableCompleted

Plan A Novel Delivery Device Study

Role: lead

All 3 trials loaded